EXERIS BIO SA provides custom solutions for the manufacturing of small molecules and recombinant proteins. The company also operates as a sales agency and chemical distributor representing custom chemical manufacturers.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Custom chemical intermediates and small molecules, from early project phases to commercial supply; including synthesis routes, volume scaling and supply-chain management.
Development Project Cost Estimation
Early cost estimates for new chemical projects, including comparison of synthesis routes; based on CAS number or structure, often within a week.
Biologics Development and Supply
Biologics focused on advanced therapeutics, nucleosides, protein drug conjugates and recombinant proteins; including supply chain, research and early-stage development.
Nucleoside Solutions
Nucleosides, nucleotides, modified nucleosides and oligonucleotides for therapeutic and diagnostic applications; with GMP-supported production and supply chain.
Protein Drug Conjugates
Protein drug conjugates for targeted therapies, with design, conjugation, purification, chemical modification, preclinical data work and partnering/licensing.
Recombinant Proteins
Recombinant proteins for therapeutic research and early development, including optimisation of expression systems, target structures and chemical modification.
Boron Neutron Capture Therapy Research (TRANSBORO)
Research project on Boron Neutron Capture Therapy with boron-based compounds, nanoparticles, scalable production and regulatory support.
Comparisons
EXERIS BIO SA in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank EXERIS BIO SA by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once EXERIS BIO SA has claimed this profile, we'll publish editorial articles and case studies here together.